Infliximab treatment of rheumatoid arthritis and Crohn's disease

Annals of Pharmacotherapy

Volumn 37, Issue 9, 2003, Pages 1256-1265

  Nahar, Ibrahim K ^a   Shojania, Kam ^a,b   Marra, Carlo A ^a,c   Alamgir, Abul H ^a   Anis, Aslam H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ARTHRITIS RESEARCH CENTRE OF CANADA   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

Crohn's disease; Infliximab; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; ETANERCEPT; FOLIC ACID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANAPHYLAXIS; CANCER; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; HEADACHE; HEALTH CARE COST; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; LUPUS ERYTHEMATOSUS; NAUSEA; PRIORITY JOURNAL; PRURITUS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; TUBERCULOSIS; URTICARIA; VACCINATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; CROHN DISEASE; HUMANS; TREATMENT OUTCOME;

EID: 0042925466     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C039     Document Type: Review

References (50)

1. Remicade full prescribing information. Revised June 2002. www.remicade.com/pdf/prescribing.pdf (accessed 2003 Feb 3).
2. Kremer JM. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med 2001;134:695-706.
3. Bell SJ, Kamm MA. The clinical role of anti-TNFα antibody treatment in Crohn's disease. Aliment Pharmacol Ther 2000;14:501-14.
4. Kalden JR. How do biologics fit into the current DMARD armamentarium? J Rheumatol 2001;28:27-35.
5. Nikolaus S, Raedler A, Kuhbacher T, Sfikas N, Folsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000;356:1475-9.
6. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
7. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999; 163:1521-8.
8. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal anti-body cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7:251-9.
9. Cornillie F, Shealy D, D'haens G, Geboes K, Van Assche G, Ceuppens J, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001;15:463-73.
10. St. Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9.
11. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
12. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359:1541-9.
13. D'haens G, van Deventer S, van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-34.
14. Present DH, Rugeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
15. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9.
16. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3490-7.
17. Lichtenstein GR. Treatment of fistulizing Crohn's disease. Gastroenterology 2000;119:1132-47.
18. Hay JW, Hay AR. Inflammatory bowel disease: cost of illness. J Clin Gastroenterol 1992;14:309-17.
19. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.
20. Saro Gismera C, Lacort Fernandez M, Arguelles Fernandez G, Anton Magarzo J, Navascues CA, Garcia Lopez R, et al. [Epidemiology of chronic inflammatory bowel disease in Gijon, Asturias]. Spanish. Gastroenterol Hepatol 2001;24:228-35.
21. Loftus EV Jr, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1998;114:1161-8.
22. Gregor JC, McDonald JWD, Klar N. An evaluation of the utility measurement in Crohn's disease. Inflamm Bowel Dis 1997;3:265-76.
23. Wong JB, Loftus EV, Sandborn WJ, Feagan BG. Estimating the cost effectiveness of infliximab for Crohn's disease. Gastroenterology 1999;116(suppl G0451, part 2):A399-400.
24. Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn's disease and perianal fistulae. Gastroenterology 2001;1120:1640-56.
25. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
26. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomized double-blind comparison of chimeric monoclonal antibody to turnout necrosis factor alpha versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
27. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998:41:1552-63.
28. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. Lancet 1999;354:1932-9.
29. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy (ATTRACT) study group. N Engl J Med 2000;343:1594-602.
30. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002;29:667-77.
31. Bala M, Noe L. Cost effectiveness of infliximab in rheumatoid arthritis (abstract). Presented at: The American College of Rheumatology Annual Scientific Meeting, Boston, October 28-November 2, 2000.
32. van Vollenhoven RF, Harju A, Bratt J, Brannemark S, Stockholm LK. Treatment with infliximab or Enbrel and employment status: data from the Stockholm TNF-alpha antagonist registry (abstract). Presented at: The American College of Rheumatology 64th Annual Scientific Meeting, San Francisco, November 10-15, 2001.
33. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
34. Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
35. Marra CA, Marion SA, Esdaile JM, Anis AH. The cost-effectiveness of infliximab plus methotrexate vs. methotrexate alone for the treatment of rheumatoid arthritis (abstract). Presented at: The Society of Medical Decision Making Annual Meeting, San Diego, October 21-24, 2001.
36. Wolfe F, Hawley DJ, Cathey MA. Termination of slow-acting antirheumatic therapy in rheumatoid arthritis: a 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
37. Galindo-Rodriguez G, Avina-Zubieta JA, Russell AS, Suarez-Almazor ME. Disappointing long-term results with disease modifying anfirheumatic drugs. A practice based study. J Rheumatol 1999;26:2337-43.
38. Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000;59:504-5.
39. Furst D, Breedveld FC, Kalden JR, Smolen JS. Building towards a consensus for the use of tumour necrosis factor blocking agents. Ann Rheum Dis 1999;58:725-6.
40. Chey WY, Hussain A, Ryan C, Potter GD, Shan A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-81.
41. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 2001;13:245-9.
42. Mikuls TR, Saag KG. Comorbidity in rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:283-315.
43. Bernstein C, Blanchard J, Kielwer E, Wajda A. Cancer risk in patients with inflammatory bowel disease. Cancer 2001;91:854-62.
44. FDA Medwatch. Infliximab product warning letter. www.fda.gov/ medwatch (accessed 2001 Oct 5).
45. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with intliximab, tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
46. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with turnout necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
47. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
48. Antoni CE, Furst D, Manger B, Lichtenstein GR, Keenan GF, Healy DE, et al. Outcome of pregnancy in women receiving Remicade (infliximab) for the treatment of Crohn's disease or rheumatoid arthritis. Arthritis Rheum 2001;44(suppl 9):600.
49. Peltier M, James D, Ford J, Wagner C, Davis H, Hanauer S. Infliximab levels in breast-milk of a nursing Crohn's patient (abstract 258). Am J Gastroenterol 2001;96(suppl):S312.
50. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE. The use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001;35:823-8. DOI 10.1345/aph.10395